PMID- 37697877 OWN - NLM STAT- MEDLINE DCOM- 20230913 LR - 20230913 IS - 0255-2930 (Print) IS - 0255-2930 (Linking) VI - 43 IP - 9 DP - 2023 Sep 12 TI - [Effects of blistering cupping combined with thunder-fire moxibustion on the efficacy and airway remodeling of cold-wheezing syndrome in bronchial asthma]. PG - 1023-7 LID - 10.13703/j.0255-2930.20221003-k0001 [doi] AB - OBJECTIVE: To investigate the clinical efficacy of the combined application of blistering cupping with thunder-fire moxibustion in treating bronchial asthma of cold-wheezing syndrome, and its influences on airway remodeling, inflammatory factors, lung function, and quality of life on the base of conventional western medicine treatment. METHODS: A total of 76 patients with bronchial asthma of cold-wheezing syndrome were randomly divided into an observation group and a control group, 38 cases in each group. In the control group, the basic treatment was used, i.e. budesonide formoterol powder inhalation. In the observation group, on the basis of the treatment as the control group, blistering cupping combined with thunder-fire moxibustion was supplemented, Dazhui (GV 14), Danzhong (CV 17) and bilateral Feishu (BL 13), Gaohuang (BL 43), and Zhongfu (LU 1) were selected; blistering cupping was administered once a day and thunder-fire moxibustion was given twice a day. One course of treatment was composed of 7 days in both groups, and 2 courses of treatment were required. Before and after treatment, the airway remodeling indexes (matrix metalloproteinase-9 [MMP-9], tissue inhibitor of matrix metalloproteinase-1 [TIMP-1], and transforming growth factor-beta1 [TGF-beta1]) and inflammatory indexes (interleukin [IL] -1beta态IL-25) were detected by using radioimmunoassay in the patients of the two groups. The lung function, traditional Chinese medicine symptom score, and asthma quality of life questionnaire (AQLQ) score were observed in the patients of the two groups. RESULTS: After treatment, the serum levels of MMP-9, TIMP-1, TGF-beta1, IL-1beta, IL-25, peak expiratory flow (PEFR), traditional Chinese medicine symptom scores, and AQLQ scores were decreased compared with those before treatment in the patients of the two groups (P<0.05), and the results in the observation group were lower than those in the control group (P<0.05). After treatment, the first second forced expiratory volume (FEV1) and peak expiratory flow rate (PEF) were increased compared with those before treatment in the two groups (P<0.05), and the results in the observation group were higher than those in the control group (P<0.05). CONCLUSION: On the basis of the conventional western medicine treatment, the combination of blistering cupping with thunder-fire moxibustion can effectively ameliorate the clinical symptoms of patients, reduce inflammatory levels, inhibit airway remodeling and improve the lung function and quality of life in the patients with bronchial asthma. FAU - Tao, Ji-En AU - Tao JE AD - Department of Acupuncture and Moxibustion, First Affiliated Hospital of Guangxi University of CM, Nanning 530001, China. FAU - Zou, Zhuo-Cheng AU - Zou ZC AD - Department of Acupuncture and Moxibustion, First Affiliated Hospital of Guangxi University of CM, Nanning 530001, China. LA - chi PT - English Abstract PT - Journal Article PT - Randomized Controlled Trial PL - China TA - Zhongguo Zhen Jiu JT - Zhongguo zhen jiu = Chinese acupuncture & moxibustion JID - 8600658 RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) SB - IM MH - Humans MH - Airway Remodeling MH - Respiratory Sounds MH - Matrix Metalloproteinase 9 MH - Transforming Growth Factor beta1 MH - *Moxibustion MH - Quality of Life MH - Tissue Inhibitor of Metalloproteinase-1 MH - *Asthma/therapy OTO - NOTNLM OT - airway remodeling OT - blistering cupping OT - bronchial asthma OT - cold-wheezing syndrome OT - inflammatory factors OT - randomized controlled trial (RCT) OT - thunder-fire moxibustion EDAT- 2023/09/12 06:41 MHDA- 2023/09/13 06:41 CRDT- 2023/09/12 03:34 PHST- 2023/09/13 06:41 [medline] PHST- 2023/09/12 06:41 [pubmed] PHST- 2023/09/12 03:34 [entrez] AID - 10.13703/j.0255-2930.20221003-k0001 [doi] PST - ppublish SO - Zhongguo Zhen Jiu. 2023 Sep 12;43(9):1023-7. doi: 10.13703/j.0255-2930.20221003-k0001.